RxDoctor Payments Data

Daniel Jacobs, MD

Neurology · Orlando, FLNPI 1356323166

Payments from drug & device makers

$1,444,306in general payments, 2019–2025

Across 1,769 payments — averaging $816.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$587K
  • F. Hoffmann-la Roche AG$351K
  • Genentech, Inc.$304K
  • Adamas Pharmaceuticals, Inc.$105K
  • EMD Serono, Inc.$22K
  • AstraZeneca$20K
  • plus $56K from 54 others

What the payments were for

  • Consulting fees$8,37522%
  • Speaking & faculty fees$2,3676%
  • Travel & lodging$1,0663%
  • Food & beverage$26,42369%
  • Education$2331%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis108$586,839
F. Hoffmann-la Roche AG82$350,962
Genentech, Inc.27$303,645
Adamas Pharmaceuticals, Inc.39$104,892
EMD Serono, Inc.108$21,954
AstraZeneca(2 entities)42$19,706
Regeneron5$17,164
Amgen(2 entities)125$9,612
Argenx US, Inc.38$5,054
AbbVie(2 entities)141$2,752
Acadia Pharmaceuticals Inc133$1,757
Mallinckrodt Hospital Products Inc.7$1,697
Sanofi71$1,632
Biogen87$1,489
Genentech USA, Inc.116$1,468
Mallinckrodt Enterprises LLC5$967
Banner Life Sciences, LLC9$963
UCB, Inc.44$887
TG Therapeutics, Inc.37$814
Lilly USA, LLC52$811
Teva Pharmaceuticals USA, Inc.75$745
Jazz Pharmaceuticals Inc.27$643
Harmony Biosciences LLC16$585
Amneal Pharmaceuticals LLC27$498
Takeda Pharmaceuticals U.S.A., Inc.16$446
Vanda Pharmaceuticals Inc.29$428
Pfizer23$405
Eisai Inc.18$396
Bristol Myers Squibb37$396
Johnson & Johnson(2 entities)15$383
Sunovion Pharmaceuticals Inc.18$370
MDD US Operations, LLC19$265
CSL Behring11$250
ANI Pharmaceuticals, Inc.11$232
GE HealthCare12$231
Lundbeck LLC10$228
Acorda Therapeutics, Inc11$197
Grifols USA, LLC9$183
Catalyst Pharmaceuticals, Inc.7$178
Neurocrine Biosciences, Inc.8$169
Alnylam Pharmaceuticals Inc.6$147
Upsher-smith Laboratories LLC7$144
Biotronik Inc.1$139
Merz Pharmaceuticals, LLC5$139
Supernus Pharmaceuticals, Inc.10$137
Cycle Pharmaceuticals Inc6$127
Biohaven Pharmaceutical Holding Company Ltd.5$104
Avadel CNS Pharmaceuticals, LLC4$103
Corium, LLC5$88
Avion Pharmaceuticals4$70
Impel Pharmaceuticals LLC2$62
E.r. Squibb & Sons, L.L.C.3$60
Axsome Therapeutics, Inc.3$59
Kyowa Kirin, Inc.3$58
Hoffmann-la Roche Limited1$56
Boston Scientific3$47
Sanofi-aventis U.S. LLC2$40
Strongbridge US Inc.3$40
Xeris Pharmaceuticals, Inc.2$40
Abbott1$39

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,444,306 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$2,033,201
Medicare patients
422
Services billed
126,539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5024$291,156
AubagioTeriflunomide22$244,708
Gamunex-CImmune Globul G/Gly/Iga Avg 4621$214,001
BetaseronInterferon Beta-1b14$151,196
NuplazidPimavanserin Tartrate12$59,957
GlatopaGlatiramer Acetate14$41,998
Glatiramer Acetate16$36,525
Dimethyl Fumarate33$27,673
QuliptaAtogepant14$26,744
UbrelvyUbrogepant16$20,414
Emgality PenGalcanezumab-Gnlm11$12,662
Dalfampridine ErDalfampridine26$9,530
Galantamine ErGalantamine Hbr90$8,844
Gabapentin251$7,247
Pyridostigmine Bromide45$6,348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$1,632$244,70822 claims
Grifols USA, LLCGamunex-C$183$214,00121 claims
Acadia Pharmaceuticals IncNuplazid$1,757$59,95712 claims
AbbVieQulipta, Ubrelvy$2,752$47,15830 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$498$6,34845 claims
Upsher-smith Laboratories LLCTopiramate$144$53826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,434 neurology providers in Florida.

Other neurology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →